PLD

105.16

+0.28%↑

DLR

172.69

+0.31%↑

CCI

107.14

+0.24%↑

CSGP

96.76

+2.16%↑

WY

25.26

+0.68%↑

PLD

105.16

+0.28%↑

DLR

172.69

+0.31%↑

CCI

107.14

+0.24%↑

CSGP

96.76

+2.16%↑

WY

25.26

+0.68%↑

PLD

105.16

+0.28%↑

DLR

172.69

+0.31%↑

CCI

107.14

+0.24%↑

CSGP

96.76

+2.16%↑

WY

25.26

+0.68%↑

PLD

105.16

+0.28%↑

DLR

172.69

+0.31%↑

CCI

107.14

+0.24%↑

CSGP

96.76

+2.16%↑

WY

25.26

+0.68%↑

PLD

105.16

+0.28%↑

DLR

172.69

+0.31%↑

CCI

107.14

+0.24%↑

CSGP

96.76

+2.16%↑

WY

25.26

+0.68%↑

Search

Alexandria Real Estate Equities Inc

Closed

SectorReal estate

77.19 1.49

Overview

Share price change

24h

Current

Min

75.5

Max

77.49

Key metrics

By Trading Economics

Income

-101M

-62M

Sales

19M

762M

P/E

Sector Avg

102.987

43.654

EPS

0.51

Dividend yield

6.4

Profit margin

-8.161

Employees

552

EBITDA

55M

487M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+27.61% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

6.40%

6.00%

Next Earnings

20 Oct 2025

Next Dividend date

14 Oct 2025

Next Ex Dividend date

29 Sept 2025

Market Stats

By TradingEconomics

Market Cap

-32M

14B

Previous open

75.7

Previous close

77.19

News Sentiment

By Acuity

67%

33%

164 / 189 Real estate

Technical Score

By Trading Central

Confidence

Bearish Evidence

Alexandria Real Estate Equities Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 Aug 2025, 21:42 UTC

Earnings
Acquisitions, Mergers, Takeovers

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 Aug 2025, 21:21 UTC

Earnings
Major Market Movers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 Aug 2025, 20:45 UTC

Earnings

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 Aug 2025, 19:15 UTC

Major Market Movers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 Aug 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 Aug 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4 Aug 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4 Aug 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 Aug 2025, 21:30 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 Aug 2025, 21:21 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 Aug 2025, 21:18 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 Aug 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4 Aug 2025, 20:25 UTC

Earnings

Transocean 2Q Loss $938M >RIG

4 Aug 2025, 20:25 UTC

Earnings

Transocean 2Q Loss/Shr $1.06 >RIG

4 Aug 2025, 20:18 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 Aug 2025, 20:15 UTC

Earnings

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 Aug 2025, 20:13 UTC

Earnings

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 Aug 2025, 20:09 UTC

Earnings

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 Aug 2025, 20:06 UTC

Earnings

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 Aug 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 Aug 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 Aug 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 Aug 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer Comparison

Price change

Alexandria Real Estate Equities Inc Forecast

Price Target

By TipRanks

27.61% upside

12 Months Forecast

Average 97 USD  27.61%

High 130 USD

Low 80 USD

Based on 8 Wall Street analysts offering 12 month price targets forAlexandria Real Estate Equities Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

3

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

73.42 / 75.585Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

No Evidence

Long Term

No Evidence

Sentiment

By Acuity

164 / 189 Real estate

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.